trial

Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study

NCTId NCT00937846
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 4 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2009-08-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
4 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2009-07-15
Primary completion
2009-08-28
Eligibility
MALE · 35 Years · 55 Years

Interventions & indications

Drugs
GSK1034702

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

2 total
London, United KingdomLondon, United Kingdom

Facts & assertions

4 sourced
Enrollment
4
Phase
PHASE1
Primary Completion Date
2009-08-28
Status
COMPLETED
relationships
The graph out of here
drug
GSK1034702
drug
lead_sponsor
GlaxoSmithKline
company
indication
Cognitive Disorders
indication
Schizophrenia
indication
Alzheimer Disease
indication